BioCryst Pharmaceuticals Résultats passés
Passé contrôle des critères 3/6
BioCryst Pharmaceuticals a connu une croissance annuelle moyenne de ses bénéfices de 29.5%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 30% par an. Les revenus ont augmenté de en hausse à un taux moyen de 39.7% par an.
Informations clés
29.54%
Taux de croissance des bénéfices
31.41%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 39.72% |
| Rendement des fonds propres | n/a |
| Marge nette | 30.16% |
| Prochaine mise à jour des résultats | 06 May 2026 |
Mises à jour récentes des performances passées
Recent updates
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real
Mar 17BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 06
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 07ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Feb 25BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
Feb 15BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Dec 09BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Sep 29Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
Aug 08Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
Jul 21Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment BioCryst Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 25 | 875 | 264 | 344 | 0 |
| 30 Sep 25 | 600 | -9 | 333 | 0 |
| 30 Jun 25 | 558 | -36 | 315 | 0 |
| 31 Mar 25 | 503 | -53 | 289 | 0 |
| 31 Dec 24 | 451 | -89 | 266 | 0 |
| 30 Sep 24 | 413 | -124 | 250 | 0 |
| 30 Jun 24 | 382 | -146 | 235 | 0 |
| 31 Mar 24 | 355 | -209 | 225 | 0 |
| 31 Dec 23 | 331 | -227 | 214 | 0 |
| 30 Sep 23 | 318 | -236 | 200 | 0 |
| 30 Jun 23 | 307 | -243 | 186 | 0 |
| 31 Mar 23 | 290 | -226 | 173 | 0 |
| 31 Dec 22 | 271 | -247 | 159 | 0 |
| 30 Sep 22 | 238 | -193 | 152 | 0 |
| 30 Jun 22 | 204 | -210 | 143 | 0 |
| 31 Mar 22 | 188 | -194 | 131 | 0 |
| 31 Dec 21 | 157 | -184 | 119 | 0 |
| 30 Sep 21 | 114 | -227 | 97 | 0 |
| 30 Jun 21 | 79 | -214 | 87 | 0 |
| 31 Mar 21 | 32 | -209 | 74 | 0 |
| 31 Dec 20 | 18 | -183 | 63 | 0 |
| 30 Sep 20 | 54 | -125 | 52 | 0 |
| 30 Jun 20 | 49 | -116 | 47 | 0 |
| 31 Mar 20 | 48 | -115 | 42 | 0 |
| 31 Dec 19 | 49 | -109 | 37 | 0 |
| 30 Sep 19 | 12 | -134 | 31 | 0 |
| 30 Jun 19 | 12 | -126 | 27 | 0 |
| 31 Mar 19 | 23 | -107 | 33 | 0 |
| 31 Dec 18 | 21 | -101 | 30 | 0 |
| 30 Sep 18 | 22 | -93 | 30 | 0 |
| 30 Jun 18 | 29 | -79 | 25 | 0 |
| 31 Mar 18 | 20 | -77 | 14 | 0 |
| 31 Dec 17 | 25 | -66 | 14 | 0 |
| 30 Sep 17 | 30 | -51 | 12 | 0 |
| 30 Jun 17 | 29 | -47 | 11 | 0 |
| 31 Mar 17 | 31 | -47 | 11 | 0 |
| 31 Dec 16 | 26 | -55 | 11 | 0 |
| 30 Sep 16 | 22 | -69 | 11 | 0 |
| 30 Jun 16 | 25 | -72 | 11 | 0 |
| 31 Mar 16 | 46 | -51 | 12 | 0 |
| 31 Dec 15 | 48 | -43 | 13 | 0 |
| 30 Sep 15 | 49 | -37 | 12 | 0 |
| 30 Jun 15 | 41 | -31 | 11 | 0 |
Des revenus de qualité: BCRX a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: BCRX est devenu rentable dans le passé.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: BCRX est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 29.5% par an.
Accélération de la croissance: BCRX est devenu rentable au cours de l'année dernière, ce qui rend le taux de croissance des bénéfices difficile à comparer à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: BCRX est devenue rentable au cours de l'année dernière, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 40.2% ).
Rendement des fonds propres
ROE élevé: Le passif BCRX dépasse son actif, il est donc difficile de calculer son rendement des capitaux propres.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/03 14:55 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
BioCryst Pharmaceuticals, Inc. est couverte par 27 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |